Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 11/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.51 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620144 | 0.85 | KMT2A (0.60) | PRSS12MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1310218 | 0.81 | DAO (0.57) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1307641 | 0.79 | KCNMA1 (0.71) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3614718 | 0.78 | PRSS12 (0.52) | PRSS12MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3618151 | 0.78 | KDM4C (0.58) | PRSS12MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1309213 | 0.78 | PRSS12 (0.64) | PRSS12MEN1KMT2AGRIK1 | |
| SCHEMBL1308714 | 0.77 | MEN1 (0.76) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1308769 | 0.77 | PPARG (0.69) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29183052 | 0.76 | GRIK1 (0.68) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1310106 | 0.76 | GRIK1 (0.74) | MEN1KMT2AGRIK1PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | PRSS12 2343/4885MEN1 2312/4885KMT2A 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.